ASS1 and neoplasm: The pegylated recombinant arginine (Arg) deiminase ADI-PEG20 (hereafter ADI will be used) has been in clinical trials against multiple tumor types, because expression of argininosuccinate synthetase 1 (ASS1), the rate-limiting enzyme for the biosynthesis of Arg, is silenced.